Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nondisjunction01:21

Nondisjunction

Nondisjunction is the failure of homologous chromosomes or sister chromatids to separate correctly and move to the opposite poles of the cells. This produces daughter cells with abnormal chromosome numbers.  Nondisjunction is common during anaphase I or anaphase II of meiosis.  Mutations in synaptonemal complex proteins that attach homologous chromosomes increase the chances of nondisjunction in anaphase I of meiosis I. In contrast, mutations in topoisomerases and condensins that hold sister...
Nondisjunction01:29

Nondisjunction

During meiosis, chromosomes occasionally separate improperly. This occurs due to failure of homologous chromosome separation during meiosis I or failed sister chromatid separation during meiosis II. In some species, notably plants, nondisjunction can result in an organism with an entire additional set of chromosomes, which is called polyploidy. In humans, nondisjunction can occur during male or female gametogenesis and the resulting gametes possess one too many or one too few chromosomes.
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Genetic Screens02:46

Genetic Screens

Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing  genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Extending the provision of cell-free DNA screening for trisomy 21.

BJOG : an international journal of obstetrics and gynaecology·2020
Same author

First trimester pre-eclampsia screening: why delay implementation?

BJOG : an international journal of obstetrics and gynaecology·2017
Same author

What will be the role of first-trimester ultrasound if cell-free DNA screening for aneuploidy becomes routine?

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2014
Same author

Reply: To PMID 23673229.

American journal of obstetrics and gynecology·2013
Same author

First-trimester placental protein 13 and placental growth factor: markers for identification of women destined to develop early-onset pre-eclampsia.

BJOG : an international journal of obstetrics and gynaecology·2010
Same author

Placental protein 13 as a first trimester screening marker for aneuploidy.

Prenatal diagnosis·2009
Same journal

Progesterone-KISS1 axis impairs amniotic epithelial cell function and promotes premature rupture of membranes.

Placenta·2026
Same journal

Placental iron-driven oxidative imbalance and changes in iron homeostasis in diabetes-in-pregnancy: A cross-sectional analytical study.

Placenta·2026
Same journal

Site-dependent differences in placental stiffness in extrachorial placenta: implications for shear wave elastography assessment.

Placenta·2026
Same journal

Placental pathology after resolved antepartum sepsis: Evidence of persistent vascular and inflammatory injury.

Placenta·2026
Same journal

GYS2 links cuproptosis and M1 macrophage polarization in preeclampsia: a functional and mechanistic analysis.

Placenta·2026
Same journal

Maternal lifetime stress and placental mitochondrial DNA mutational load: Effect modification by maternal characteristics.

Placenta·2026
See all related articles

Related Experiment Video

Updated: Jun 5, 2026

Semiconductor Sequencing for Preimplantation Genetic Testing for Aneuploidy
09:03

Semiconductor Sequencing for Preimplantation Genetic Testing for Aneuploidy

Published on: August 25, 2019

Screening for pre-eclampsia--lessons from aneuploidy screening.

H S Cuckle1

  • 1Department of Obsterics and Gynecology, Columbia University Medical Center, 622 W. 168th Street, PH1666, New York, NY 10032, USA. h.s.cuckle@leeds.ac.uk

Placenta
|January 25, 2011
PubMed
Summary
This summary is machine-generated.

This study suggests adapting aneuploidy screening methods for pre-eclampsia detection. Early and late-onset pre-eclampsia cases could be identified with high accuracy using first-trimester screening markers.

More Related Videos

FISH for Pre-implantation Genetic Diagnosis
07:34

FISH for Pre-implantation Genetic Diagnosis

Published on: February 23, 2011

Pre-Implantation Genetic Testing for Aneuploidy on a Semiconductor Based Next-Generation Sequencing Platform
09:30

Pre-Implantation Genetic Testing for Aneuploidy on a Semiconductor Based Next-Generation Sequencing Platform

Published on: August 17, 2022

Related Experiment Videos

Last Updated: Jun 5, 2026

Semiconductor Sequencing for Preimplantation Genetic Testing for Aneuploidy
09:03

Semiconductor Sequencing for Preimplantation Genetic Testing for Aneuploidy

Published on: August 25, 2019

FISH for Pre-implantation Genetic Diagnosis
07:34

FISH for Pre-implantation Genetic Diagnosis

Published on: February 23, 2011

Pre-Implantation Genetic Testing for Aneuploidy on a Semiconductor Based Next-Generation Sequencing Platform
09:30

Pre-Implantation Genetic Testing for Aneuploidy on a Semiconductor Based Next-Generation Sequencing Platform

Published on: August 17, 2022

Area of Science:

  • Obstetrics and Gynecology
  • Maternal-Fetal Medicine
  • Biostatistics in Healthcare

Background:

  • Antenatal screening for aneuploidy is a global standard in clinical practice.
  • Established statistical methodologies used for aneuploidy screening may be adaptable for pre-eclampsia detection.
  • Pre-eclampsia screening requires robust statistical models for accurate risk assessment.

Purpose of the Study:

  • To evaluate the feasibility of adapting aneuploidy screening methodologies for pre-eclampsia detection.
  • To assess the potential of first-trimester screening markers for identifying early and late-onset pre-eclampsia.
  • To model the performance of a combined screening approach using maternal serum markers and physical parameters.

Main Methods:

  • Systematic review of published literature on pre-eclampsia screening markers.
  • Utilizing first-trimester maternal serum markers (PP13, PAPP-A, PlGF, ADAM12, inhibin A) and physical parameters (MAP, uterine artery Doppler PI).
  • Estimating individual risks by integrating prior risk with likelihood ratios derived from clinical factors and screening marker profiles, employing a multivariate Gaussian model.

Main Results:

  • Sufficient data exists to estimate individual pre-eclampsia risks with reasonable accuracy.
  • Modeling indicates that combining PAPP-A with another serum marker and physical markers can detect over two-thirds of early-onset and one-third of late-onset pre-eclampsia cases at a <2% high-risk rate.
  • A 5% high-risk classification rate could achieve detection of three-quarters of early-onset pre-eclampsia cases.

Conclusions:

  • First-trimester screening programs for aneuploidy could be extended to include pre-eclampsia screening, offering high detection rates.
  • While further data on specific markers is needed, current modeling shows promising results for integrated screening.
  • Prospective studies are essential to validate the predictive performance of the proposed pre-eclampsia screening model.